troglitazone has been researched along with Anemia in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rothwell, C | 1 |
| McGuire, EJ | 1 |
| Altrogge, DM | 1 |
| Masuda, H | 1 |
| de la Iglesia, FA | 1 |
1 other study available for troglitazone and Anemia
| Article | Year |
|---|---|
Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone.
Topics: Administration, Oral; Anemia; Animals; Area Under Curve; Bile Ducts, Intrahepatic; Cholesterol; Chro | 2002 |